An open - label extension study of the safety and efficacy of risperidone in <font color="red">children_7</font> <font color="red">and_7</font> <font color="red">adolescents_7</font> <font color="red">with_7</font> <font color="red">autistic_7</font> <font color="red">disorder_7</font> <font color="red">._7</font> <font color="red">
<br>
<br>_1</font> OBJECTIVE The purpose of this study was to evaluate the <font color="red">long_1</font> <font color="red">-_1</font> <font color="red">term_1</font> <font color="red">safety_1</font> <font color="red">and_1</font> <font color="red">efficacy_1</font> <font color="red">of_1</font> <font color="red">risperidone_1</font> <font color="red">in_1</font> <font color="red">treating_1</font> <font color="red">irritability_1</font> <font color="red">and_1</font> <font color="red">related_1</font> <font color="red">behaviors_1</font> <font color="red">in_1</font> <font color="red">children_7</font> <font color="red">and_7</font> <font color="red">adolescents_7</font> <font color="red">with_7</font> <font color="red">autistic_7</font> <font color="red">disorders_7</font> <font color="red">._7</font> <font color="red">
<br>_3</font> METHODS In this 6 month ( 26 week ) open - label extension ( OLE ) study , <font color="red">patients_4</font> <font color="red">(_4</font> <font color="red">5_4</font> <font color="red">-_4</font> <font color="red">17_4</font> <font color="red">years_4</font> <font color="red">of_4</font> <font color="red">age_4</font> <font color="red">,_4</font> <font color="red">who_3</font> <font color="red">completed_3</font> <font color="red">the_3</font> <font color="red">previous_3</font> <font color="red">fixed_3</font> <font color="red">-_3</font> <font color="red">dose_3</font> <font color="red">,_3</font> <font color="red">6_3</font> <font color="red">week_3</font> <font color="red">,_3</font> <font color="red">double_3</font> <font color="red">-_3</font> <font color="red">blind_3</font> <font color="red">[_3</font> <font color="red">DB_3</font> <font color="red">]_3</font> <font color="red">phase_3</font> <font color="red">)_3</font> <font color="red">were_1</font> <font color="red">flexibly_1</font> <font color="red">dosed_1</font> <font color="red">with_1</font> <font color="red">risperidone_1</font> <font color="red">based_1</font> <font color="red">on_1</font> <font color="red">body_1</font> <font color="red">weight_1</font> <font color="red">._1</font> <font color="red">The_1</font> <font color="red">maximum_1</font> <font color="red">allowed_1</font> <font color="red">dose_1</font> <font color="red">was_1</font> <font color="red">1.25_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">day_1</font> <font color="red">for_1</font> <font color="red">those_1</font> <font color="red">weighing_1</font> <font color="red">20_1</font> <font color="red">to_1</font> <font color="red"><_1</font> <font color="red">45_1</font> <font color="red">kg_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">1.75_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">day_1</font> <font color="red">for_1</font> <font color="red">those_1</font> <font color="red">weighing_1</font> <font color="red">≥_1</font> <font color="red">45_1</font> <font color="red">kg_1</font> <font color="red">._1</font> <font color="red">The_1</font> <font color="red">study_1</font> <font color="red">primarily_1</font> <font color="red">assessed_1</font> <font color="red">risperidone_1</font> <font color="red">'s_1</font> <font color="red">safety_1</font> <font color="red">;_1</font> <font color="red">efficacy_1</font> <font color="red">was_1</font> <font color="red">assessed_1</font> <font color="red">as_1</font> <font color="red">a_1</font> <font color="red">secondary_1</font> <font color="red">end_1</font> <font color="red">-_1</font> <font color="red">point_1</font> <font color="red">._1</font> <font color="red">
<br>_1</font> RESULTS <font color="red">Fifty_4</font> <font color="red">-_4</font> <font color="red">six_4</font> <font color="red">(_4</font> <font color="red">71%_4</font> <font color="red">)_4</font> <font color="red">out_4</font> <font color="red">of_4</font> <font color="red">79_5</font> <font color="red">enrolled_5</font> <font color="red">patients_5</font> <font color="red">completed_4</font> <font color="red">the_4</font> <font color="red">OLE_4</font> <font color="red">;_4</font> the most common discontinuations were for insufficient response ( 7 [ 9% ] ) or adverse events ( AE ) ( 5 [ 6% ] ) . The most common ( ≥ 5% frequency in the total group ) AEs were increased appetite ( 11% [ n=9 ] ) ; increased weight and vomiting ( 9% [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8% [ n=6 ] each ) ; nasopharyngitis ( 6% [ n=5 ] ) ; and somnolence and fatigue ( 5% [ n=4 ] each ) . Extrapyramidal AEs were reported in 6 ( 8% ) patients . Increase in mean weight ( 11 - 15% ) and body mass index ( 5 - 10% ) occurred ; one patient discontinued because of weight increase . One potentially prolactin - related AE ( irregular menstruation ) was reported . The risperidone high - dose group had the greatest mean improvement in sleep visual analog scale ( 24.6 ) . All groups showed additional improvement in efficacy scale scores during the OLE . 
<br> CONCLUSIONS During this OLE , safety findings with risperidone treatment ( maximum weight - based dose of 1.25 mg / day or 1.75 mg / day ) were consistent with those observed in the DB phase , and with the current safety information for risperidone in autistic , psychiatric , and behavioral disorders . Patients experienced some additional improvement in irritability and related behaviors . 
<br> CLINICAL TRIALS REGISTRY This phase-4 study is registered at ClinicalTrials.gov ( NCT00576732 ) .